###### Strengths and limitations of this study

-   Only patients with ST-segment elevation myocardial infarction (STEMI) receiving successful primary percutaneous coronary intervention (pPCI) and defined Δapelin-12 with apelin-12 elevation per cent 72 hours after pPCI compared with apelin-12 level immediately prior to pPCI were enrolled.

-   The prognosis value of apelin-12 in predicting short-term (during hospitalisation) and long-term (2.5 years) major adverse cardiovascular events, respectively, was analysed among patients with estimated glomerular filtration rate exceeding and below 90 mL/min×1.73m^2^.

-   The relatively small cohort size may affect the statistical results; therefore, a larger-scale study is warranted.

-   The basic level of apelin prior to STEMI onset is difficult to measure; therefore, the degree of reduction in apelin is unknown.

-   This study focuses only on apelin-12, and the analysis of other forms of apelin is suggested.

Introduction {#s1}
============

ST-elevation myocardial infarction (STEMI) following successful primary percutaneous coronary intervention (pPCI) is the leading cause of mortality and morbidity worldwide in major adverse coronary events (MACEs) due to mechanical complications, acute heart failure and cardiac shock after successful procedure.[@R1] Structural and functional alterations lead to progressive worsening of cardiac performance. The prognosis of STEMI following pPCI is influenced by several clinical, biochemical and echocardiographic factors. Novel, more reliable biomarkers are urgently needed to precisely identify patients at high risk for adverse clinical outcomes in the follow-up period after pPCI and to aid in the development of individualised prevention programme.[@R2]

Apelin, a 77-amino acid peptide is the endogenous ligand for the human orphan G protein-coupled receptor (APJ) and is secreted by white adipose tissue. It is expressed in various cardiovascular tissues, including endothelial cells, coronary vessels, vascular smooth muscle cells and cardiomyocytes.[@R4] The apelin--APJ system plays a role in cardiovascular homoeostasis.[@R5] Apelin-12 may employ its cardioprotective profile via the complex mechanism of improving hypertension, insulin resistance, obesity and cardiovascular risk factors.[@R6] However, the use of serum apelin-12 level on admission in providing additional prognostic information among patients with STEMI receiving pPCI remains unknown. There is limited evidence examining the involvement of apelin in STEMI and some research suggests it has no prognostic value,[@R9] and one study found an inverse correlation between the level of apelin-12 and prognosis.[@R12] These results highlight the need for additional research.

This study aims to determine the ability of plasma apelin-12 levels to predict short-term and long-term MACEs in patients with STEMI following successful pPCI. Furthermore, the combined use of estimated glomerular filtration rate (eGFR) is examined.

Methods {#s2}
=======

Inclusion and exclusion criteria and definition of MACEs {#s2a}
--------------------------------------------------------

Patients were enrolled in the study if they presented with the onset of symptoms of STEMI at the First People's Hospital of Taizhou, Zhejiang, China between January 2010 and October 2014. STEMI symptoms included: persistent chest pain (\>30 min), prolonged ECG changes (including ischaemic ST-segment elevation in two or more contiguous leads and/or depression) and significantly increased serum myocardial enzyme and troponin concentrations. Written informed consent was obtained, and the Research Ethics Committee of The First People's Hospital of Taizhou approved the study.

Exclusion criteria included non-STEMI; severe vascular heart disease; balloon angioplasty alone; rescue PCI; conservative treatment without PCI; previous onset of ventricular fibrillation; cardiogenic shock; untreated third or advanced degree of atrioventricular block; estimated life expectancy \<12 months; secondary hypertension; endocrine diseases such as thyroid dysfunction or adrenal cortical dysfunction; history of cerebrovascular attack (within 1 year) or cerebrovascular attack with a significant residual neurological deficit; a history of chronic hepatitis or cirrhosis; severe renal insufficiency needing dialysis; known contraindication to statins, heparin, aspirin, clopidogrel, contrast or glycoprotein IIb/IIIa inhibitor (GPI); recent serious infection, connective tissue disease; malignancy; active severe bleeding; significant gastrointestinal or genitourinary bleeding; major surgery or trauma within 6 weeks and incomplete clinical data.

Important definitions {#s2b}
---------------------

A MACE is defined as the composite of cardiac death, recurrent target vessel myocardial infarction (RMI); clinically driven target lesion revascularisation (TLR); cardiogenic shock or demonstrated congestive heart failure. The eGFR was estimated using the simplified Modification of Diet in Renal Disease formula.[@R13] Δapelin-12 was defined as the level of apelin-12 elevation 72 hours after pPCI compared with apelin-12 level immediately before pPCI.

Therapy process {#s2c}
---------------

A total of 464 patients underwent successful pPCI all of whom were diagnosed with STEMI and admitted to emergency room within 12 hours from onset. All patients received 300 mg oral aspirin and clopidogrel as well as standard heparin (initial 10 000 IU and boost during surgery), patients with high thrombotic burden use the GPI (uniformly tirofiban in our centre), which was determined by our interventional physician. Ultrasound scans were taken within 5 days after PCI (median 4.2 days). The parameters of two-dimensional echocardiography and Doppler were measured using standard methods (ie, using biplane Simpson's method for measuring left ventricular volumes and ejection fraction). Volumes were expressed as indices by normalising with body surface area.

All the patients received 30-month follow-up after pPCI until MACEs. A small number of patients suffered MACEs requiring hospitalisation. Patients were organised into MACEs group and non-MACEs group and independent predictors of poor prognosis were identified. The following biochemical indicators were measured: blood (including haemoglobin, neutrophil per cent, haemoglobin and platelet), coagulation, D-dimer, renal and hepatic function, ∆apelin-12, peak myocardial enzyme, lipid level and fast blood glucose on the second day. Patients were further stratified into two subgroups according to the median value of apelin-12 level on admission and into three further subgroups according to tertiles of eGFR.

Apelin-12 ELISA detection {#s2d}
-------------------------

Serum was isolated by centrifugation within 1 hour at 2500 g for 10 min and stored at −80°C. Serum concentrations of apelin-12 were assayed using commercially available enzyme immunoassay kits (Phoenix Pharmaceuticals, Belmont, California, USA). The protocol was as follows: add 50 µL/well of standard, sample or positive control, 25 µL of primary antibody and 25 µL of biotinylated peptide; incubate at room temperature (20--23°C) for 2 hours; wash immunoplate four times with 350 µL/well of 1×assay buffer; add 100 µL/well of Streptavidin horse radish peroxidase-solution and incubate at room temperature for 1 hour. Wash immunoplate four times with 350 µL/well of 1×assay buffer. Add 100 µL/well of 3,3′, 5,5′-tetramethylbenzidine substrate solution and incubate at room temperature for 1 hour. Terminate reaction with 100 µL/well of 2N HCl. The detection limit was 0.1 mg/L, with 1.26% and 5.4% intra-assay and interassay coefficients of variation, respectively. The measurements were performed in triplicates.

Statistical strategy {#s2e}
--------------------

Continuous data were presented as mean ± SD or medians with interquartile ranges, whereas categorical data were presented as a percentage, unless otherwise denoted. Univariate cox analysis and log-rank test were used for qualitative and quantitative variables to determine whether there is significant difference between the MACE and non-MACE groups. Variables with P\<0.1 in the above analysis were selected for the multivariate cox proportional hazard analysis. The adjusted HR and 95% CI were calculated. The log-rank test was used to compare Kaplan-Meier curves of MACE-free survival in the two groups, divided by the median apelin-12. Finally, the receiver operating characteristic (ROC) analysis was used to identify the appropriate cut-off value of potential predictive indicators. The cut-off point was the maximum sum of sensitivity and specificity. The ROC curves were conducted with the Medcalc V.12.3.0.0. All statistical tests were two tailed, performed using SPSS V.17.0, and a P value \<0.05 was considered statistically significant.

Results {#s3}
=======

Baseline characteristics of patients in individual groups {#s3a}
---------------------------------------------------------

Of the 464 enrolled patients, 118 (25.4%) had MACEs in the 2.5-year follow-up. Nineteen (4.1%) patients suffered cardiac death, while 27 (5.8%) suffered RMI; 85 (18.3%) received TLR due to RMI or progressive stenosis. Thirty-five (7.5%) performed cardiogenic shock or demonstrated congestive heart failure onset. Among the MACEs group, 31 (6.7%) patients reached end point during hospitalisation. Twenty-one (4.5%) patients lost to follow-up after discharge ([figure 1](#F1){ref-type="fig"}). Basic clinical characteristics, laboratory examinations, ECG results, angiographic and procedural characteristics are depicted in [table 1](#T1){ref-type="table"}.

![Patients selecting process and results reported. MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.](bmjopen-2017-018595f01){#F1}

###### 

Basic clinical characteristics, laboratory examinations, ECG results, angiographic and procedural characteristic

                                       MACEs (n=118)         Non-MACEs (n=346)     P Value
  ------------------------------------ --------------------- --------------------- -----------
  Clinical characteristics                                                         
   Age, years                          67.0±12.2             61.7±11.6             0.252
   Female, n (%)                       33 (28.0)             76 (22.0)             0.184
   Heart rate, beats per min           79.5±19.5             76.1±16.6             0.118
   SBP, mm Hg                          132.2±26.6            131.6±25.0            0.277
   Anterior wall MI, n (%)             72 (61.0)             159 (46.0)            0.005\*
   Killip's classification\>I, n (%)   41 (34.7)             71 (20.5)             0.002\*
   Diabetes mellitus, n (%)            41 (34.7)             109 (31.5)            0.515
   Hypertension, n (%)                 72 (61.0)             193 (55.8)            0.321
   Previous MI, n (%)                  19 (16.1)             36 (10.4)             0.098
  Lab examination                                                                  
   Apelin-12, ng/mL                    0.69 (0.53--0.87)     0.79 (0.63--1.03)     \<0.001\*
   Δapelin-12 (%)                      13.9 (5.6--17.6)      14.7 (5.3--22.3)      0.092
   WBC×10^9^/L                         10.6±3.86             9.86±3.58             0.161
   Neutrophil (%)                      76.8±12.6             74.9±12.4             0.064
   Haemoglobin, g/L                    139.4±16.7            145.3±17.1            0.546
   Platelet×10^9^/L                    240.2±60.1            227.8±57.2            0.264
   Albumin, g/L                        37.9±3.9              38.0±3.8              0.424
   TC, mmol/L                          5.87±0.99             5.57±1.17             0.469
   TG, mmol/L                          1.06±0.65             1.12±0.90             0.261
   HDL-C, mmol/L                       1.25±0.28             1.18±0.27             0.982
   LDL-C, mmol/L                       3.07±0.72             3.03±0.73             0.744
   FBG, mmol/L                         7.67±2.68             7.66±2.48             0.207
   BUN, mmol/L                         6.78±1.88             6.72±2.14             0.387
   Creatinine, mmol/L                  76.3±15.6             74.1±21.7             0.392
   Uric acid, mmol/L                   333.3±80.7            338.5±72.9            0.153
   eGFR mL/min\*1.73 m^2^              89.7±25.8             100.6±25.9            0.067
   D-Dimer, mg/L                       0.7 (0.2--1.6)        1.0 (0.2--1.7)        0.247
   Peak CK-MB, U/L                     131.5 (51.6--208.5)   103.0 (39.3--193.4)   0.252
   Peak cTnI, ng/mL                    21.5 (9.3--32.4)      12.6 (3.0--28.8)      0.014\*
  Treatment                                                                        
   ACEIs/ARBs, n (%)                   94 (79.7)             294 (85.0)            0.178
   b-blocker, n (%)                    65 (55.1)             211 (61.0)            0.260
   CCBs, n (%)                         29 (24.6)             101 (29.2)            0.335
   Statins, n (%)                      97 (82.2)             288 (83.2)            0.796
   Diuretics, n (%)                    19 (16.1)             55 (15.9)             0.958
   tirofiban, n (%)                    15 (12.7)             52 (15.0)             0.536
  Echocardiogram and ECG                                                           
   LAD, mm                             38.5±5.3              37.0±5.7              0.311
   LVEDD, mm                           52.0±6.4              49.9±6.1              0.273
   LVEF, %                             47.3±9.4              51.9±7.3              0.010\*
   Pathological Q-wave, n (%)          70 (59.3)             153 (44.2)            0.005\*
   GENSINI                             85.0 (48.8--100.1)    66.9 (37.2--101.7)    0.129
  Culprit vessels, n (%)                                                           
   LAD                                 64 (54.2)             169 (48.8)            0.557
   LCX                                 18 (15.3)             54 (15.6)             
   RCA                                 36 (30.5)             123 (35.5)            
   Stent number                        1.33±0.55             1.39±0.57             0.524

Data are n/N (%) or mean ±SD or median (25th--75th percentile).

\*P\<0.05.

ACEIs, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BUN, blood urea nitrogen; CCBs, calcium channel blockers; CK-MB, creatine kinase MB; cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HDL-C, high-density lipoprotein; LAD, left atrial diameter; LCX, left circumflex coronary artery; LDL-C, low-density lipoprotein-cholesterol; LVEDD, left ventricular and diastolic diameter; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; MI, myocardial infarction; RCA, right coronary artery; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyeride; WBC, white blood cells.

Multivariate logistic regression analysis of predictor of MACEs {#s3b}
---------------------------------------------------------------

Significant differences were found between the two groups in peak cardiac troponin I (cTnI) (21.5 (9.3--32.4) vs 12.6 (3.0--28.8), P=0.014) and left ventricular ejection fraction (LVEF) (47.3%±9.4% vs 51.9%±7.3%, P=0.010). Consistent with the hypothesis, patients who suffered from MACEs had lower apelin-12 on admission (0.69 (0.53--0.87) vs 0.79 (0.63--1.03), P\<0.001). Anterior wall MI, pathological Q-wave and higher Killip's classification were found more in the MACEs group compared with survivals (P=0.005, 0.005 and 0.002, respectively). Differences in Δapelin-12 (13.9 (5.6--17.6) vs 14.7 (5.3--22.3), P=0.092), neutrophil per cent (76.8±12.6 vs 74.9±12.4, P=0.064), eGFR (89.7±25.8 vs 100.6±25.9, P=0.067) and previous MI proportion (16.1% vs 10.4%, P=0.098) were approaching significance between the two groups.

Through the multivariate cox regression analysis, low apelin-12 (HR=0.132, 95% CI 0.060 to 0.292, P\<0.001), low eGFR (HR=0.985, 95% CI 0.977 to 0.993, P\<0.001), low LVEF (HR=0.965, 95% CI 0.941 to 0.991, P=0.007) and pathological Q-wave (HR=1.536, 95% CI 1.058 to 2.230, P=0.024) were independent predictors of MACEs within 2.5 years after pPCI, along with Killip's classification\>I (HR=0.610, 95% CI 0.408 to 0.912, P=0.016). Anterior wall MI was moderately predictive of MACEs within 2.5 years (HR=1.421, 95% CI 0.970 to 2.082, P=0.071) ([table 2](#T2){ref-type="table"}).

###### 

Multivariate cox regression analysis for predictor of MACEs

  Variables                    P value     OR      95**%** CI
  ---------------------------- ----------- ------- ----------------
  Anterior wall MI             0.071       1.421   0.970 to 2.082
  Previous MI                  0.708       1.107   0.650 to 1.884
  Apelin-12                    \<0.001\*   0.132   0.060 to 0.292
  Δapelin-12 (%)               0.411       0.991   0.970 to 1.012
  Neutrophil (%)               0.186       1.011   0.995 to 1.027
  eGFR                         \<0.001\*   0.985   0.977 to 0.993
  cTnI                         0.203       1.017   0.991 to 1.044
  LVEF                         0.007\*     0.965   0.941 to 0.991
  Pathological Q-wave          0.024\*     1.536   1.058 to 2.230
  Killip's classification\>I   0.016       0.610   0.408 to 0.912

\*Statistically significant value (\<0.05).

cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; MI, myocardial infarction.

Survival analysis {#s3c}
-----------------

Kaplan-Meier curves in patients with higher (\>0.76 ng/mL, n=229) and lower (\<0.76 ng/mL, n=235) apelin-12 during 2.5-year follow-up (without MACEs during hospitalisation) is shown in [figure 2](#F2){ref-type="fig"}. Significant differences in event-free survival were noted between patients with differing apelin-12 on admission (P=0.018).

![Kaplan-Meier curves in patients with STEMI with individual levels of apelin-12 during 2.5 years of follow-up (without MACEs during hospitalisation). MACE, major adverse cardiovascular events; STEMI, ST-segment elevation myocardial infarction.](bmjopen-2017-018595f02){#F2}

ROC analysis of predictor of MACEs {#s3d}
----------------------------------

ROC analysis failed to find the area under curve (AUC) of any indicator for 2.5-year MACEs exceeding 0.7, although the P value for apelin-12, eGFR and LVEF alone was 0.0001, 0.0369 and 0.0015, respectively, while the AUC of Δapelin-12 for 2.5-year MACEs was 0.547 (95% CI 0.500 to 0.593, P=0.0906, [figure 3](#F3){ref-type="fig"}). When only in-hospital MACEs were observed, there was no evidence of predictive value except for LVEF\<52% (AUC=0.674, 95% CI 0.629 to 0.716, P=0.0005) and apelin-12 ≤0.64 ng/mL (AUC=0.623, 95% CI 0.577 to 0.667, P=0.0169, [figure 4](#F4){ref-type="fig"} and [table 3](#T3){ref-type="table"}). ROC analysis ofΔapelin-12 found a higher AUC with a cut-off point of 20% only for those with apelin-12 on admission ≤0.76 ng/mL (P=0.0075, [table 3](#T3){ref-type="table"}).

###### 

ROC analysis for in-hospital and 2.5-year MACEs

  Parameters              AUC     95% CI           P Value    Threshold   Sensitivity, %   Specificity, %
  ----------------------- ------- ---------------- ---------- ----------- ---------------- ----------------
  2.5-year MACEs                                                                           
   Δapelin-12             0.547   0.500 to 0.593   0.0906     20%         91.53            30.64
   apelin-12              0.619   0.573 to 0.663   0.0001\*    0.87       75.36            42.03
   eGFR                   0.565   0.518 to 0.611   0.0369\*   86.13       53.39            63.87
   LVEF                   0.597   0.551 to 0.642   0.0015\*   50%         59.32            56.94
  Apelin-12\>0.76 ng/mL                                                                    
   Δapelin-12             0.530   0.454 to 0.605   0.4767     17%         92.31            39.81
   Apelin-12≤0.76 ng/mL                                                                    
   Δapelin-12             0.613   0.547 to 0.675   0.0075\*   20%         100.00           30.77
  In-hospital MACEs                                                                        
   Δapelin-12             0.507   0.460 to 0.553   0.8711     20%         3.23             73.44
   apelin-12              0.623   0.577 to 0.667   0.0169\*    0.64       51.61            70.67
   eGFR                   0.543   0.497 to 0.589   0.4021     86.98       58.06            59.12
   LVEF                   0.674   0.629 to 0.716   0.0005\*   52%         83.87            43.42

\*Statistically significant value (P\<0.05).

AUC, area under curves; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; ROC, receiver operating characteristic.

![Receiver operating characteristic curve of apelin-12, eGFR, LVEF and Δapelin-12 for predicting 2.5 year MACEs after pPCI among patients with STEMI. eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; pPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.](bmjopen-2017-018595f03){#F3}

![Receiver operating characteristic curve of apelin-12, eGFR, LVEF and Δapelin-12 for predicting in-hospital MACEs after pPCI among patients with STEMI. eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; pPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.](bmjopen-2017-018595f04){#F4}

When patients were further subdivided according to eGFR, it was found that 224 patients with eGFR were over 90 mL/min×1.73 m^2^. Among these patients, apelin-12 had a predictive advantage for MACEs compared with Δapelin-12 (P=0.0115) and eGFR (P=0.0071). Moreover, LVEF was only predictive in patients with eGFR\>90 mL/min×1.73 m^2^ (AUC=0.628, 95% CI 0.564 to 0.689, P=0.0039, [table 4](#T4){ref-type="table"}), in other words, among patients with eGFR over 90 mL/min×1.73 m^2^, apelin-12 perform the most ideal prognostic factor.

###### 

ROC analysis for 2.5-year MACEs among patients with separate level of renal function

  Parameters                          AUC     95% CI           P value    Threshold   Sensitivity, %   Specificity, %
  ----------------------------------- ------- ---------------- ---------- ----------- ---------------- ----------------
  eGFR\>90 mL/min×1.73 m^2^ (n=244)                                                                    
   Δapelin-12                         0.524   0.459 to 0.588   0.5556     20%         90.57            29.84
   apelin-12                          0.664   0.601 to 0.723   0.0001\*    0.65       66.04            58.12
   eGFR                               0.508   0.443 to 0.572   0.8634     91.67       100              7.33
   LVEF                               0.628   0.564 to 0.689   0.0039\*   50%         62.26            61.78
  eGFR\<90 mL/min×1.73 m^2^ (n=220)                                                                    
   Δapelin-12                         0.566   0.498 to 0.633   0.0885     20%         92.31            31.61
   apelin-12                          0.654   0.587 to 0.716   0.0001\*    0.89       67.69            60.65
   eGFR                               0.562   0.494 to 0.629   0.1186     86.13       96.92            19.35
   LVEF                               0.561   0.492 to 0.627   0.1651     51%         63.08            48.39

\*Statistically significant value compared with apelin-12 (P\<0.05).

AUC, area under curves; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; ROC, receiver operating characteristic.

Discussion {#s4}
==========

The clinical outcomes in patients with STEMI receiving pPCI are closely associated with the pre-PCI apelin-12 concentration, particularly among those with normal renal function. In further subgroup analysis, the change of apelin during hospitalisation was found to predict long-term prognosis among patients with low apelin level on admission (apelin-12 ≤0.76 ng/mL).

Apelin may then play a role in assessing risk stratification among patients with STEMI given its role in the pathophysiology of both heart failure and ischaemia/reperfusion injury.[@R14] Apelin has been found to increase contractility and reduce peripheral resistance via endothelial nitric oxide (NO)-dependent signalling[@R15] in failing myocardial cells to slow the pathological progress of heart failure.[@R16] Apelin expression has been found to decline in decompensated states, whereas it is maintained or augmented in stable chronic heart failure.[@R17]

In patients with stable angina, plasma apelin was negatively associated with coronary artery stenosis severity independent of other cardiovascular risk factors.[@R18] Weir and colleagues demonstrated plasma apelin level is reduced immediately after acute myocardial infarction but increases markedly after revascularisation. Despite this, it remains depressed at 24 weeks.[@R19] A potential explanation of lower levels of apelin following STEMI include: (1) the demand of apelin among patients with STEMI increases; therefore, more apelin is consumed immediately after MI episodes; (2) product plunging due to MI. A recent study demonstrated the flow-mediated adjustment of the apelin/APJ system in human endothelial cells and found apelin-12 expression is induced by shear stress independently of its ligand, particularly during reperfusion.[@R20] Further, hypoxia-inducible factor-mediated pathways participate in the apelin upregulation in myocardium, pulmonary circulation and skeletal muscles following systemic hypoxic exposure or myocardial injury.[@R21] Therefore, the apelin--APJ system may alleviate the myocardial reperfusion mediated oxidative stress and apoptosis by increasing superoxide dismutase degradation, thereby decreasing the generation of reactive oxygen species, along with upregulating endothelial constitutive nitric oxide synthase (eNOS) levels and activating ERK1/2 phosphorylation signalling.[@R22] The above results may be responsible for the poor short-term outcomes and long-term prognosis observed in patients with low levels of apelin.

Apelin can provide myocardial protection against ischaemic damage by decreasing permeability of microvascular endothelial cells via upregulating the expression of Tie-2 and vascular endothelial growth factor receptor 2 (VEGFR2),[@R23] and improving neovascularisation via recruiting circulating Aplnr +cells during early-phase myocardial repair.[@R24] The Apelin--APJ system promotes angiogenesis and provides nutrients and oxygen to the ischaemic area in MI animal models.[@R25] Apelin gene therapy by myocardial injection ameliorates cardiac repair, improves cardiac metabolism via activating Sirt3 and upregulating VEGF/VEGFR2 expression in post-MI mice.[@R26] Conversely, apelin downregulation exacerbates ischaemia--reperfusion injury and myocardial infarction adverse remodelling.[@R25] A recently published study proved apelin 12 is able to protect prothrombotic effects of other adipokine such as apelin-13.[@R28] Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production.[@R29] The use rate of angiotensin-converting enzyme inhibitors and β-blockers was similar among patients with different prognosis in the present study, eliminating the drug-derived influence on angiotensin activity. Myeloid cell-derived leucine-rich α2-glycoprotein attenuates adverse cardiac remodelling after MI via upregulating the expression of apelin receptor.[@R30] Direct anti-inflammatory[@R31] and antiatherogenic properties[@R32] are also reported as mechanisms of atherosclerotic lesions and aortic aneurysms prevention by apelin. Stress-induced apoptosis in serious cardiovascular diseases is inhibited by cardiac apelin expression elevation.[@R33] TIMP3 maintains metabolic flexibility via apelin during cardiac stress seizure.[@R34] Taken together, the above cardiovascular profile suggests a beneficial effect of apelin on atherosclerosis and makes apelin--APJ system a promising therapeutic target in acute coronary syndrome.[@R35]

Liu and colleagues[@R36] have demonstrated the effect of serum apelin-12 in predicting 1 year outcomes following pPCI in patients with STEMI. Topuz and colleagues[@R37] found lower levels of serum apelin-12 predicts higher incidence of in-hospital MACEs after multivariate regression analysis and is more likely in no-reflow versus normal flow group. This is a result of NO-dependent vasodilatation caused by apelin-12 in clinical studies[@R38] as well as in animal models.[@R39] Abnormal level of apelin and a series of adipokines observed in patients with acute MI resulted in a high incidence of MACEs during 3-year follow-up.[@R40] Low apelin appears to correlate with carotid plaque vulnerability in patients with carotid stenosis. Atorvastatin-induced apelin modification may beneficially affect carotid plaque stability.[@R41]

We hypothesise the potential explanation of the subgroup analysis according to different renal function is that patients with relatively normal level of eGFR fail to perform enough discrepancy to distinguish high-risk patients, to these patients, our novel index apelin-12 show its superiority in predicting MACEs.

This study is not without limitations. The study cohort was relatively small. which may affect the statistical results. A larger-scale study is warranted to further assess the risk of long-term MACEs after pPCI in patients with STEMI. The base level of apelin prior to STEMI onset is difficult to obtain, therefore the degree of apelin reduction is unknown. Finally, this study only focused on apelin-12, analysis on other forms of apelin is recommended.

Conclusion {#s5}
==========

In conclusion, patients with STEMI receiving pPCI with lower levels of apelin-12 are more likely to have poor short-term and long-term prognosis after adjusting for other clinical parameters. Furthermore, apelin-12 may be beneficial in predicting MACEs among patients with eGFR\>90 mL/min×1.73 m^2^.
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